BeyondSpring Receivables 2015-2025 | BYSI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BeyondSpring receivables from 2015 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BeyondSpring receivables from 2015 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$229.7B
Amgen (AMGN)	$153.5B
Gilead Sciences (GILD)	$149.5B
Vertex Pharmaceuticals (VRTX)	$96B
Bristol Myers Squibb (BMY)	$93.5B
CSL (CSLLY)	$83.2B
GSK (GSK)	$76.9B
Regeneron Pharmaceuticals (REGN)	$57.9B
Alnylam Pharmaceuticals (ALNY)	$57B
Argenex SE (ARGX)	$39.1B
BioNTech SE (BNTX)	$26.3B
Insmed (INSM)	$23.9B
Royalty Pharma (RPRX)	$20.3B
Biogen (BIIB)	$18.8B
Incyte (INCY)	$15.5B
Illumina (ILMN)	$14.6B
Genmab (GNMSF)	$14.3B
Genmab (GMAB)	$13.5B
Ascendis Pharma (ASND)	$12B
BioMarin Pharmaceutical (BMRN)	$10.9B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Exelixis (EXEL)	$10.1B
Moderna (MRNA)	$9.9B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$7.9B
Halozyme Therapeutics (HALO)	$7.7B
Exact Sciences (EXAS)	$7.7B
Roivant Sciences (ROIV)	$7.6B